APA (7th ed.) Citation

Alten, R., Burmester, G., Matucci-Cerinic, M., Salmon, J., Zaremba-Pechmann, L., Fakhouri, W., . . . Fautrel, B. (2022). POSA370 Healthcare Resource Use By European Patients Enrolled in RA-be-Real: A Multinational, Prospective, Observational Study of the Effectiveness, Healthcare Resource Utilization and Costs in Patients with Rheumatoid Arthritis Receiving Baricitinib, Targeted Synthetic or Biologic Disease Modifying Therapies. Value in Health, 25(1), S221. https://doi.org/10.1016/j.jval.2021.11.1081

Chicago Style (17th ed.) Citation

Alten, R., et al. "POSA370 Healthcare Resource Use By European Patients Enrolled in RA-be-Real: A Multinational, Prospective, Observational Study of the Effectiveness, Healthcare Resource Utilization and Costs in Patients with Rheumatoid Arthritis Receiving Baricitinib, Targeted Synthetic or Biologic Disease Modifying Therapies." Value in Health 25, no. 1 (2022): S221. https://doi.org/10.1016/j.jval.2021.11.1081.

MLA (9th ed.) Citation

Alten, R., et al. "POSA370 Healthcare Resource Use By European Patients Enrolled in RA-be-Real: A Multinational, Prospective, Observational Study of the Effectiveness, Healthcare Resource Utilization and Costs in Patients with Rheumatoid Arthritis Receiving Baricitinib, Targeted Synthetic or Biologic Disease Modifying Therapies." Value in Health, vol. 25, no. 1, 2022, p. S221, https://doi.org/10.1016/j.jval.2021.11.1081.